We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cyclophosphamide, Adriamycin, 5-Fluorouracil and High-dose Toremifene for Patients with Advanced/Recurrent Breast Cancer.
- Authors
Tominaga, Takeshi; Nomura, Yasuo; Uchino, Junichi; Hirata, Koichi; Kimura, Morihiko; Yoshida, Minoru; Aoyama, Hideaki; Kinoshita, Hiroaki; Koyama, Hiroki; Monden, Yasumasa; Takashima, Shigemitsu; Ogawa, Michio
- Abstract
Background: Multi-combination chemotherapy consisting of anthracyclines has been effective but has not invariably prolonged the survival period in advanced/recurrent breast cancer. The possibility has been discussed that chemoendocrine therapy combined with endocrine agents is more effective.Methods: In order to evaluate the toxicity and efficacy of a new endocrine therapy for advanced/recurrent breast cancer, we ran a pilot study during the period from July 1994 to July 1996.Results: Twenty-two patients with advanced/recurrent breast cancer were treated with chemoendocrine therapy consisting of cyclophosphamide (100 mg/body) p.o. daily for 14 days, with adriamycin (40 mg/m2) i.v. and 5-fluorouracil (500 mg/body) i.v. on day 1 (repeated every 3 weeks for 9 weeks) (CAF therapy), and high-dose toremifene (120 mg/body) p.o. daily. Of 20 evaluable patients, two showed complete response (10%), eight partial response (40%), six no change (30%) and four progressive disease (20%). The overall response rate was 50%, and the median duration of response was 69.5 days (28–133+ days). The major toxicities were drug-induced alopecia, gastrointestinal toxicity and hematological toxicity, but these were clinically well tolerated. No serious cardiac, liver or renal symptom was seen.Conclusions: Based on these results, we consider the addition of high-dose toremifene to the CAF therapy to be useful in the treatment of advanced and recurrent breast cancer.
- Publication
Japanese Journal of Clinical Oncology, 1998, Vol 28, Issue 4, p250
- ISSN
0368-2811
- Publication type
Article